Clinical effect of Babaodan capsules combined with transcatheter arterial chemoembolization therapy in patients with primary hepatocellular carcinoma
10.3760/cma.j.issn.1006-9801.2017.09.006
- VernacularTitle:八宝丹胶囊联合肝动脉栓塞化疗治疗原发性肝癌的临床疗效
- Author:
Mingzhi HAO
1
;
Hailan LIN
;
Qizhong CHEN
;
Yubin HU
Author Information
1. 福建省肿瘤医院介入科 福建省肿瘤转化医学重点实验室
- Keywords:
Liver neoplasms;
Chemoembolization;
therapeutic;
Chinese herbal;
Babaodan capsules
- From:
Cancer Research and Clinic
2017;29(9):602-606
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of Babaodan capsules combined with transcatheter arterial chemoembolization (TACE) therapy in patients with BCLC stage B primary hepatocellular carcinoma (HCC). Methods A total of 32 patients with BCLC B primary hepatocellular carcinoma who cannot be treated with operation in the Department of Oncology in Fujian Province Cancer Hospital from May 2010 to March 2013 were enrolled in the experimental group. According to paired design, 64 patients with BCLC B primary liver cancer who were treated with only TACE were as control. The patients of experimental group were treated with Babaodan capsules combined with TACE, and the patients of control group were treated with only TACE. Overall response rate (ORR), time to progression (TTP), overall survival (OS), liver function change 1 week after TACE, and post-embolization syndromes were analyzed. Measurement data were compared using t test, count data were compared with χ2test. Kaplan-Meier method was used for survival analysis, and Log-rank method for testing. Results The ORR 1.5 month after TACE was 75.0%in experimental group and 81.3%in control group(P=0.477). The median TTP was 8.9 months(95%CI 3.1-14.7 months) in experimental group, and 5.5 months (95%CI 4.3-6.7 months) in control group (P=0.048). The median OS time was 16 months(95%CI 8.0-24.0 months) in experimental group, and 12 months(95%CI 11.0-13.0 months) in control group (P=0.159). Compared with the experimental group, the alanine transaminase 1 week after TACE in control group increased obviously (P=0.018). The incidence rate of ≥CTCAE grade 2 pain after the first time TACE in experimental group was lower than that in control group(P=0.019). Conclusion Babaodan capsules could reduce pain of HCC patients after TACE, improve liver damage after TACE,and prolong the TTP of patients with BCLC stage B HCC.
